Bad news for the Chesapeake Bay: It's getting hot
The study estimates the Chesapeake Bay area could have marine heat wave conditions for about a third of the year by the end of the century. That's an increase from the 22 days a year the bay now sees long periods of unusually high water temperatures.
Specifically, the study focuses on estuaries — areas where freshwater meets salt water, such as the lower Chesapeake Bay. Researchers looked at estuaries across the U.S. to analyze trends in marine heat waves.
These extended heat waves can have negative effects on local wildlife, especially if prolonged. That couild include mass mortality of local species, habitat loss, species migration and increased ocean stressors such as low pH and dissolved oxygen. Heat waves can critically disrupt essential processes in an ecosystem, according to VIMS.
Piero Mazzini, a professor at VIMS and coauthor of the study, said the research should 'serve as a warning' for local leaders in charge of taking care of environmental assets.
Environment | 'I've got fish on my roof': Fierce weather brings more than rain for Hampton man
Environment | First national analysis finds America's butterflies are disappearing at 'catastrophic' rate
Environment | Help could be on the way for Chincoteague water wells contaminated by PFAS
Environment | Scientists raise concerns as the US stops sharing air quality data from embassies worldwide
Environment | Trump wants to use the 'God Squad' to increase logging, but it must follow strict rules
'The Chesapeake Bay, for example, currently experiences marine heat wave conditions approximately 6% of the year — 22 days per year — and that is already placing stress on the ecosystem,' Mazzini said. 'Our study shows that estuaries across the East Coast could experience these conditions for more than 100 days of the year by 2100.'
Estuaries serve as important nursery habitats for nearly 75% of all fish species and support more than 54 million jobs, according to the study. East Coast areas also were found to fare worse than the West Coast, where winds can churn cooler water toward the surface.
A previous study from VIMS found the bay has warmed by about 2 degrees Fahrenheit, or about .07 degrees each year, since the mid-1980s. Hot summer days already bring problems with low oxygen, and heat excites oxygen molecules so they leave the liquid more easily. This results in 'dead zones,' areas where oxygen is removed faster than it can be replenished. Animals need healthy levels of oxygen in the water to survive.
In 2024, environmental groups reported that the Chesapeake Bay dead zone was at a near-average size, but despite progress, officials still warn that the bay will not meet 2025 goals for restoration.
If actions do not change, the study found that warming trends in climate are expected to persist throughout the 21st century, and some projections suggest that much of the open ocean could be in a 'near-permanent' marine heat wave toward the end of the century. The rise of sea-surface temperatures is a main driver of issues for estuaries, and environmental scientists are looking to reducing greenhouse gases and increasing tree canopy as potential solutions.
Ricardo Nardi, lead author on the study, said open ocean temperatures have a long history of being studied, but estuaries are often overlooked. Longer heat wave conditions could have 'disastrous ecosystem consequences,' so more research is needed to understand how conditions in the ocean and estuaries affect each other.
'These are critical ecosystems, and future conservation efforts will depend on our understanding of the factors influencing them,' Nardi said.
Eliza Noe, eliza.noe@virginiamedia.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results
We recently published . AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best healthcare stocks. AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotech company specializing in discovering and developing therapeutic antibodies across various disease areas, including cancer, metabolic, endocrine, and autoimmune disorders. Their integrated platform combines technology, data science, and collaboration to identify promising antibody candidates. In recent developments, AbCellera Biologics Inc. (NASDAQ:ABCL) began dosing participants in a Phase 1 clinical trial for ABCL635, targeting vasomotor symptoms related to menopause, marking a key clinical milestone. The company reported strong Q2 2025 revenue growth, beating expectations and advancing both internal and partnered antibody programs despite ongoing net losses. Some analysts note that its innovative pipeline and expanding clinical presence could place it among the best healthcare stocks to watch in the biotech space. Photo by Myriam Zilles on Unsplash This Phase 1 trial signals the corporation's shift from primarily a discovery platform to a clinical-stage biotech with proprietary assets. Progress with ABCL635 addresses a significant unmet medical need and validates its platform's potential to develop first-in-class therapeutics. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
The Hill
16 hours ago
- The Hill
Samples before space suits: America must be smart about its mission to Mars
On day one of this administration, the president included his ambitions for Mars in his inaugural address, and again several weeks later to a joint session of Congress: 'We are going to conquer the vast frontiers of science, and we are going to lead humanity into space and plant the American flag on the planet Mars, and even far beyond.' President Trump's vision for Mars is correct, and now there is a plan for the next steps in how he achieves it. The U.S. has led the world in the exploration of Mars since Vikings I and II landed in 1976. We now stand on the precipice of two ultimate achievements: the return of samples from Mars to Earth, and sending the first humans — Americans — to the Martian surface. The fiscal 2026 presidential budget request proposed 'to terminate the Mars Sample Return Program given that current architecture options remain unaffordable.' But, it adds: 'It is anticipated that future missions to Mars will return samples for study on Earth.' We need those samples robotically returned for study on Earth. Delaying Mars Sample Return or waiting for astronauts to pick them up will make the human exploration of Mars significantly more expensive and dangerous — and for the first time ever, almost certainly cede decades of U.S. space exploration leadership to China. A lower-cost robotic Mars Sample Return would more than pay for itself from savings realized by simplified human missions. Martian soil has substances known to be toxic, as well as uncharacterized biological potential. Without Mars Sample Return, human mission designs must account for the full range of possibilities and the most demanding scenarios. Laboratory tests are needed to make direct measurements of the Mars samples to determine concentrations and forms of toxic materials to understand threats and develop solutions. This will be needed to design spacesuits and protect astronauts from the fine martian dust. It allows risk mitigation to shift from large and expensive requirements to quantifiable ones with reduced uncertainties. While no martian life has been detected yet, our exploration has shown that much of Mars would previously have been habitable, and parts of Mars may currently still be habitable. In advance of humans to Mars, we need to robotically return samples in a highly controlled manner to satisfy planetary protection back-contamination requirements to ensure that Mars does not have organisms that might impact human health or have adverse effects on Earth's biosphere. Mars Sample Return will accelerate U.S. leadership in space. Mars is several hundred times farther from Earth than the Moon. Using current propulsion technologies, a Mars round trip will take up to three years, with minimal abort opportunities, as compared to Apollo's round trip of days. Even then, there were three uncrewed and four crewed missions before Apollo 11, the first Moon landing. Completing Mars Sample Return supports technology demos needed for human missions, such as advancing from the current precision landing (7-10 km) to pinpoint landing (~100 m) to put astronauts in proximity to safe sites and pre-positioned supplies. Mars Sample Return also achieves a profound international first: the first samples — with potential for evidence of life — returned from Mars. These samples might once and for all answer the fundamental question of 'Are we alone in the universe,' and that is a question we most certainly want the United States to answer first. Lockheed Martin, my former employer, has been studying Mars Sample Return missions for more than 50 years, and is confident it can deliver an end-to-end architecture for under $3 billion — less than half of previous estimates — by leveraging heritage components, reducing design complexity, and streamlining the program structure. They have built and flown four highly successful Mars landers and four highly successful Mars orbiters, as well as pioneered all three of NASA's previous sample return missions (returning material from a comet, the solar wind and an asteroid), and have established credibility and mission success across a wide variety of additional deep space missions, from Venus to Saturn. NASA's Mars 2020 rover, Perseverance or 'Percy,' at Jezero Crater has been caching an unparalleled set of samples that will shed more light on the history of Mars than all previous Mars missions combined. China has announced it plans to launch a sample return mission to Mars in 2028, with an Earth return likely in 2031. If we forgo the timely return of Percy's superior set of samples, it will be China that leaps ahead. Mars soil and dust are uniquely different, and potentially dangerous — returning samples should precede astronauts going to Mars, while also maintaining our nation's pre-eminence in Mars exploration as NASA lays the groundwork for the next giant leap. Ben Clark has been a member of the science teams of every NASA mission to explore the surface of Mars, and designed the instrument on Viking that made the first analysis of martian soil. He was chief scientist for deep space exploration at Lockheed Martin. Currently, he helps analyze chemical compositions of the diverse samples the Perseverance rover has been acquiring during its multi-year trek on Mars.
New York Times
a day ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
